Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
WOBURN, Mass. , Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for
View HTML
Toggle Summary NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
WOBURN, Mass. , Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in
View HTML
Toggle Summary NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
WOBURN, Mass. , Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023 . This live, interactive, online event will give shareholders and the investment community the opportunity to interact in
View HTML
Toggle Summary NeuroMetrix Reports Q2 2023 Business Highlights
WOBURN, Mass. , July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes through
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
WOBURN, Mass. , July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 27,
View HTML
Toggle Summary NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
WOBURN, Mass. , July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell ® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the
View HTML
Toggle Summary Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
WOBURN, Mass. , June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people with diabetes. Ke and colleagues developed and validated an algorithm to predict progression from
View HTML
Toggle Summary Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
WOBURN, Mass. , June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK . The scientific poster was titled "Abnormal combined diabetic peripheral neuropathy (DPN)-check and SUDOSCAN
View HTML
Toggle Summary Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
WOBURN, Mass. , May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH -funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for
View HTML
Toggle Summary NeuroMetrix Reports Q1 2023 Financial Results
WOBURN, Mass. , May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023 . The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population
View HTML